olmutinib

Ligand id: 9196

Name: olmutinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 110.86
Molecular weight 486.18
XLogP 4.56
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Cha MY, Ha TH, Jeon JY, Jo MG, Kang SJ, Kim MS, Kim MR, Kwak EJ, Lee JY, Lee KO, Suh KH. (2012)
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity.
Patent number: WO2011162515. Assignee: Hanmi Holdings Co. , Ltd.. Priority date: 30/06/2010. Publication date: 03/05/2012.
2. Kim ES. (2016)
Olmutinib: First Global Approval.
Drugs76 (11): 1153-7. [PMID:27357069]
3. MY Cha, Kang SJ, Kim MR, Lee JY, Jeon JY, Jo MG, Kwak EJ, Lee KO, Ha TH, Suh KH, Kim MS. (2013)
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity.
Patent number: US20130116213. Assignee: Hanmi Science Co., Ltd.. Priority date: 23/06/2010. Publication date: 09/05/2013.
4. Park JK, Byun JY, Park JA, Kim YY, Lee YJ, Oh JI, Jang SY, Kim YH, Song YW, Son J et al.. (2015)
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis Res. Ther.18: 91. [PMID:27090981]
5. Park K, Han JY, Kim DW, Bazhenova LA, Ou SH, Pang YK, Hin HS, Juan O, Son J, J√§nne P. (2016)
190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).
J Thorac Oncol11 (4 Suppl): S139. [PMID:27198328]
6. Park K, Lee JS, Han JY, Lee KH, Kim JH, Cho EK, Cho JY, Min YJ, Kim JS, Kim DW. (2016)
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.
J Thorac Oncol11 (4 Suppl): S113. [PMID:27198272]